Established in August 2014, Shenzhen TargetRx is a Sino-American joint venture that specializes in the research and development of targeted drugs. The company has received investments from prominent angel investors in China. The company aims to become a global leader in the development of targeted drugs, particularly in the field of small molecule anti-cancer drugs. Shenzhen TargetRx has dedicated itself to developing innovative anti-tumor drugs to improve the lives of cancer patients. It is focused on designing, screening, evaluating, optimizing, and researching a series of original, third-generation small molecule anti-tumor drugs with independent intellectual property rights. The company aims to overcome the challenge of acquired drug resistance and work towards transforming cancer into a chronic disease.

Disease Domain	Count

Neoplasms	8
Hemic and Lymphatic Diseases	6
Immune System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	9

Top 5 Target	Count

Bcl-2 x Bcl-xl(Apoptosis regulator Bcl-2 x Apoptosis regulator Bcl-X)	1
ALK x ROS1(Anaplastic lymphoma kinase x Proto-oncogene tyrosine-protein kinase ROS)	1
HIF-PHs(Hypoxia-inducible factor prolyl hydroxylase)	1
EGFR T790M(Epidermal Growth Factor Receptor T790M)	1
FLT3(Tyrosine-protein kinase receptor FLT3)	1

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 02 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

IND Application

Phase 1 Clinical

Phase 2 Clinical

Phase 3 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TGRX-326 ( ALK x ROS1 )	ALK positive Non-Small Cell Lung Cancer More	Phase 3
TGRX-814 ( Bcl-2 x Bcl-xl )	Hematologic Neoplasms More	Phase 2 Clinical
TGRX-678 ( Bcr-Abl T315I )	Philadelphia chromosome positive chronic myelogenous leukemia More	Phase 1
TGRX-1942 ( PTK7 )	Solid tumor More	IND Application
TGRX-072 ( ALK x EGFR )	Non-Small Cell Lung Cancer More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis